X4 PHARMACEUTICALS, INC Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
X4 PHARMACEUTICALS, INC (XFOR) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $1.50 per share for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-09.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2024-03-21
- X4 PHARMACEUTICALS, INC share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2021-03-31 was $7.08, a 4.07% decline year-over-year.
- X4 PHARMACEUTICALS, INC share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2020-03-31 was $7.38, a 7.74% increase year-over-year.
- X4 PHARMACEUTICALS, INC share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2019-03-31 was $6.85.
- X4 PHARMACEUTICALS, INC share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $1.50, a 78.81% decline from fiscal 2021.
- X4 PHARMACEUTICALS, INC share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2021 was $7.08, a 2.34% decline from fiscal 2020.
- X4 PHARMACEUTICALS, INC share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2020 was $7.25, a 2.84% increase from fiscal 2019.
- X4 PHARMACEUTICALS, INC share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2019 was $7.05, a 8.29% increase from fiscal 2018.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2023-09-30 | $1.50 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $1.50 10-Q · filed 2023-08-10 | |||
| 2022-12-31 | $1.50 10-K · filed 2024-03-21 | |||
| 2021-12-31 | $7.08 10-K · filed 2022-03-17 | |||
| 2021-09-30 | $7.08 10-Q · filed 2021-11-04 | |||
| 2021-06-30 | $7.08 10-Q · filed 2021-08-03 | |||
| 2021-03-31 | $7.08 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | $7.25 10-K · filed 2021-03-19 | |||
| 2020-09-30 | $7.25 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | $7.38 10-Q · filed 2020-08-04 | |||
| 2020-03-31 | $7.38 10-Q · filed 2020-05-07 | |||
| 2019-12-31 | $7.05 10-K · filed 2020-03-12 | |||
| 2019-09-30 | $6.90 10-Q · filed 2019-11-07 | |||
| 2019-06-30 | $6.68 10-Q · filed 2019-08-07 | |||
| 2019-03-31 | $6.85 10-Q · filed 2019-05-15 | |||
| 2018-12-31 | $6.51 10-K · filed 2019-03-11 | |||
| 2018-09-30 | $7.25 10-Q · filed 2018-11-09 | |||
| 2018-06-30 | $7.25 10-Q · filed 2018-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |